Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Pivotal data sets up Tecentriq filing in small cell lung cancer

Pivotal data sets up Tecentriq filing in small cell lung cancer

Roche’s PD-L1 inhibitor Tecentriq has become the first cancer immunotherapy to improve survival in extensive-stage small cell lung cancer (ES-SCLC), putting it on course to end a ... Small cell lung cancer is less common that the non-small cell lung

Latest news

More from news
Approximately 1 fully matching, plus 517 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... TROP-2 is a cell surface receptor which is over-expressed by many human tumours, including cancers of the breast, colon and

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... This month's big pharma collaborations are in oncology, firstly where Novartis and BMS have entered a clinical

  • Pharma deals during August 2014 Pharma deals during August 2014

    Oncothyreon's clinical stage pipeline includes the immunotherapy candidates tecemotide (phase III - Stage III non-small cell lung cancer) and ONT-10 (phase 1 - solid tumour treatment), and the only ... 2 small molecule inhibitor in clinical development,

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Oncology drugs under AMNOG: part two. Patient-relevant outcomes and the 'added benefit' of cancer drugs. ... Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is

  • BIND Therapeutics appoints Andrew Hirsch as permanent CEO BIND Therapeutics appoints Andrew Hirsch as permanent CEO

    Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

  • Axelar appoints Carl Harald Janson as CEO

    I look forward to take this potential novel cancer treatment to proof-of-concept,” said Janson. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • How pembrolizumab will change the management of advanced lung cancer

    How pembrolizumab will change the management of advanced lung cancer. The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by ... He explains that “ this data will completely change our

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

  • Therapy Watch expands its oncology portfolio

    Therapy Watch expands its oncology portfolio. This month  Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics